2026Q2 CRISPR Therapeutics AG

Incorporated on October 28, 2013, as a Swiss stock corporation (Aktiengesellschaft) under the name Inception Genomics AG (renamed CRISPR Therapeutics AG on April 28, 2014) and headquartered at Baarerstrasse 14 in Zug, Switzerland, with primary research and development operations in Boston and Framingham, Massachusetts, CRISPR Therapeutics AG is a commercial-stage biotechnology company developing transformative gene-based medicines21. Although domiciled in Switzerland, the company files domestic U.S. GAAP periodic reports (Forms 10-K, 10-Q, and 8-K) with the U.S. Securities and Exchange Commission as a well-known seasoned issuer

The company's foundational technology is built upon Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a bacterial adaptive immune mechanism programmed to cleave double-stranded genomic DNA at precise target sequences25. Co-founder Dr. Emmanuelle Charpentier, alongside Dr. Jennifer Doudna, was awarded the 2020 Nobel Prize in Chemistry for elucidating the CRISPR/Cas9 gene-editing mechanism12. CRISPR Therapeutics holds exclusive therapeutic rights to Dr. Charpentier's foundational patent estate and has expanded its technological architecture to include next-generation base and gene-correction platforms (CRISPR-X and SyNTase), lipid nanoparticle (LNP) in vivo delivery vehicles, allogeneic cell engineering, and small interfering RNA (siRNA) therapeutics2